Quantitation of intratumoral @entity1382 expression predicts for resistance to protracted infusion of @entity1487 and weekly leucovorin in disseminated XXXX : preliminary report from an ongoing trial.

@entity1 @entity217 @entity1382 @entity5 @entity14 @entity1487
A clinical trial for @entity1 with measurable, disseminated @entity14 is being conducted to determine: (1) if intratumoral expression of @entity1382 ( @entity1382 ) affects response to protracted-infusion @entity1487 ( @entity1487 ); and (2) whether intratumoral expression of @entity1382 increases when clinical resistance is found after response to @entity1487 . Polymerase chain reaction technology is employed to determine @entity1382 expression. Using @entity217 as an internal standard, @entity1382 expressions for 26 @entity1 range from 0.5 x 10(-3) to 22.6 x 10(-3). Currently, 22 @entity1 are evaluable for response and @entity1382 quantitation of their measurable @entity5 . 8 @entity1 (36%) have had partial responses; 3 responding @entity1 had been previously treated with @entity1487 . A strong statistical association between @entity1382 expression and resistance to therapy has been found (P = 0.004). No @entity1 with @entity1382 expression of 4.0 x 10(-3) or greater has responded. On average, @entity1 previously treated with @entity1487 have slightly higher levels of @entity1382 expression in their measurable @entity5 (P = 0.4). Whether responding @entity1 will develop increased expressions of @entity5 remains to be determined. Confirmation of these results in a larger cohort could lead to a scientific rationale for deciding upon specific therapy for @entity1 with disseminated @entity14 .
